DK1382351T3 - Kombinationsterapi med angiotensinomdannende enzyminhibitor og epoxysteroidal aldosteronantagonist til behandling af cardiovaskulær sygdom - Google Patents

Kombinationsterapi med angiotensinomdannende enzyminhibitor og epoxysteroidal aldosteronantagonist til behandling af cardiovaskulær sygdom

Info

Publication number
DK1382351T3
DK1382351T3 DK03019610T DK03019610T DK1382351T3 DK 1382351 T3 DK1382351 T3 DK 1382351T3 DK 03019610 T DK03019610 T DK 03019610T DK 03019610 T DK03019610 T DK 03019610T DK 1382351 T3 DK1382351 T3 DK 1382351T3
Authority
DK
Denmark
Prior art keywords
combination therapy
cardiovascular disease
converting enzyme
enzyme inhibitor
angiotensin converting
Prior art date
Application number
DK03019610T
Other languages
English (en)
Inventor
John C Alexander
Barbara Roniker
Subhash Desai
Original Assignee
Searle Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle Llc filed Critical Searle Llc
Application granted granted Critical
Publication of DK1382351T3 publication Critical patent/DK1382351T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DK03019610T 1999-03-05 2000-03-03 Kombinationsterapi med angiotensinomdannende enzyminhibitor og epoxysteroidal aldosteronantagonist til behandling af cardiovaskulær sygdom DK1382351T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12297799P 1999-03-05 1999-03-05

Publications (1)

Publication Number Publication Date
DK1382351T3 true DK1382351T3 (da) 2006-01-23

Family

ID=22406014

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03019610T DK1382351T3 (da) 1999-03-05 2000-03-03 Kombinationsterapi med angiotensinomdannende enzyminhibitor og epoxysteroidal aldosteronantagonist til behandling af cardiovaskulær sygdom
DK00912174T DK1165136T3 (da) 1999-03-05 2000-03-03 Kombinationsterapi af angiotensinomdannende enzyminhibitor og epoxy-steriodal aldosteronantagonist til behandling af cardiovaskulær sygdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK00912174T DK1165136T3 (da) 1999-03-05 2000-03-03 Kombinationsterapi af angiotensinomdannende enzyminhibitor og epoxy-steriodal aldosteronantagonist til behandling af cardiovaskulær sygdom

Country Status (24)

Country Link
US (1) US20040077611A1 (da)
EP (2) EP1382351B8 (da)
JP (1) JP2002538172A (da)
KR (1) KR100580286B1 (da)
CN (1) CN1229141C (da)
AR (1) AR029155A1 (da)
AT (2) ATE310537T1 (da)
AU (2) AU778559B2 (da)
BR (1) BR0008781A (da)
CA (1) CA2364169A1 (da)
DE (2) DE60024335T2 (da)
DK (2) DK1382351T3 (da)
EA (1) EA004064B1 (da)
ES (2) ES2250803T3 (da)
HK (2) HK1042252B (da)
HU (1) HUP0200519A2 (da)
IL (2) IL145237A0 (da)
MX (1) MXPA01009035A (da)
NZ (1) NZ514205A (da)
PT (1) PT1165136E (da)
SI (1) SI1165136T1 (da)
TR (1) TR200102581T2 (da)
WO (1) WO2000051642A1 (da)
ZA (1) ZA200107779B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041535A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Eplerenone crystalline form
EP1580193A3 (en) * 1999-12-08 2010-06-23 Pharmacia Corporation Eplerenone crystalline form
AU784946B2 (en) * 1999-12-08 2006-08-03 Pharmacia Corporation Eplerenone crystalline form exhibiting enhanced dissolution rate
EP1505072A3 (en) * 1999-12-08 2006-06-21 Pharmacia Corporation Eplerenone crystalline form exhiniting enhanced dissolution rate
AU2001255730A1 (en) * 2000-04-26 2001-11-07 First Horizon Pharmaceutical Corporation Methods and compositions for the treatment of cardiac indications
US20020111337A1 (en) * 2000-08-28 2002-08-15 Fedde Kenton N. Use of an aldosterone receptor antagonist to improve cognitive function
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US20070112593A1 (en) * 2005-11-14 2007-05-17 Rxcera Pharmaceutical, Inc. Selection system, dispensing system and treatment with a one-a-day combination pill for hypertension, hypercholesterolemia, hypertriglyceridemia and anti-platelet treatment
US20100318371A1 (en) * 2009-06-11 2010-12-16 Halliburton Energy Services, Inc. Comprehensive hazard evaluation system and method for chemicals and products
WO2014018930A1 (en) * 2012-07-27 2014-01-30 Isis Pharmaceuticals. Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
CN106267147A (zh) * 2015-06-10 2017-01-04 上药东英（江苏）药业有限公司 一种复方降压药物组合物
BR112018005223B1 (pt) 2015-10-08 2022-08-09 Ionis Pharmaceuticals, Inc Compostos, uso dos mesmos, e composição farmacêutica
IL302817A (en) 2020-11-18 2023-07-01 Ionis Pharmaceuticals Inc Compounds and methods for modulating angiotensinogen expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040255A2 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
ES2167571T3 (es) * 1995-06-07 2002-05-16 Searle & Co Terapia de combinacion de antagonista de aldosterona epoxi-esteroideo y antagonista de angiotensina ii para el tratamiento del fallo cardiaco congestivo.

Also Published As

Publication number Publication date
MXPA01009035A (es) 2004-08-12
IL145237A (en) 2006-08-01
DE60005159D1 (de) 2003-10-16
HK1042252A1 (en) 2002-08-09
EP1382351A1 (en) 2004-01-21
DK1165136T3 (da) 2004-01-12
CN1229141C (zh) 2005-11-30
AU3394500A (en) 2000-09-21
ES2250803T3 (es) 2006-04-16
BR0008781A (pt) 2002-07-02
EP1165136B1 (en) 2003-09-10
NZ514205A (en) 2004-07-30
EP1382351B1 (en) 2005-11-23
AU2005201045A1 (en) 2005-04-07
JP2002538172A (ja) 2002-11-12
EP1165136A1 (en) 2002-01-02
CA2364169A1 (en) 2000-09-08
PT1165136E (pt) 2004-02-27
HK1061200A1 (en) 2004-09-10
DE60024335D1 (de) 2005-12-29
KR20010108319A (ko) 2001-12-07
WO2000051642A1 (en) 2000-09-08
ES2206204T3 (es) 2004-05-16
HK1042252B (zh) 2004-04-23
IL145237A0 (en) 2002-06-30
TR200102581T2 (tr) 2002-04-22
EA200100951A1 (ru) 2002-04-25
DE60024335T2 (de) 2006-08-03
HUP0200519A2 (hu) 2002-07-29
US20040077611A1 (en) 2004-04-22
AR029155A1 (es) 2003-06-18
KR100580286B1 (ko) 2006-05-16
ATE310537T1 (de) 2005-12-15
SI1165136T1 (en) 2004-02-29
ZA200107779B (en) 2002-12-20
AU778559B2 (en) 2004-12-09
EP1382351B8 (en) 2006-03-08
EA004064B1 (ru) 2003-12-25
ATE249242T1 (de) 2003-09-15
CN1372475A (zh) 2002-10-02
DE60005159T2 (de) 2004-07-22

Similar Documents

Publication Publication Date Title
DK1382351T3 (da) Kombinationsterapi med angiotensinomdannende enzyminhibitor og epoxysteroidal aldosteronantagonist til behandling af cardiovaskulær sygdom
NO20012229D0 (no) Kombinasjonsbehandling med angiotensin-konverterende enzyminhibitor og aldosteron-antagonist for reduksjon avmorbiditet og mortalitet ved kardiovaskul¶re sykdommer
NO20030761D0 (no) Farmasöytisk kombinasjon av angiotensin II antagonister og angiotensin I konverterende enzyminhibitorer
NO20013393L (no) Bronnsementeringsfremgangsmater og sammensetninger
PT2075000E (pt) Combinação de azelastina e ciclesonida
DK1212317T3 (da) Indolderivater og anvendelse deraf til behandling af osteoporose blandt andre anvendelser
NO20013356D0 (no) Forsinkede tiksotropiske sementsammensetninger og fremgangsmåter
NO20015274D0 (no) ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav
DE60318317D1 (de) Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren
NO20016395L (no) Effekt- og föringsforbindelse
AU2003217916A8 (en) Stable formulations of angiotensin converting enzyme (ace) inhibitors
DK1682395T3 (da) Fremgangsmåde og system til hjælp for afviklingen af trafikken af arbejdstog
WO2002009759A3 (en) Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
DK1178981T3 (da) Substituerede 3-pyridyl-4-arylpyrroler og deres terapeutiske og profylaktiske anvendelser
AU2003290417A8 (en) Process for the preparation of angiotensin converting enzyme (ace) inhibitors and its use
DK1381620T3 (da) Hypersulfaterede disaccharider og fremgangsmåder til anvendelse af samme til behandling af inflammationer
DE69813083D1 (de) Kombination in feste Dosiermenge von Angiotensin-Converting-Enzyme-Hemmern mit Calcium-Kanal Antagonisten zur Behandlung von Herz-Kreislauferkrankungen
PL371436A1 (en) Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
ATE269853T1 (de) Benzoxa- und benzthiazolylsulfamate sowie ihre verwendung als steroid-sulfataseinhibitoren
GB0201513D0 (en) Construction and design of foundation elements
MXPA03001509A (es) Combinacion farmaceutica de antagonistas de la angiotensina ii e inhibidores de la enzima de conversion de la angiotensina i.
DE50011237D1 (de) Abstichvorrichtung sowie Abstichverfahren
BR9607612A (pt) Terapia de combinaç o de inibidor de enzima de conversão de angiotensina quantidade de reduzido efeito colateral de antagonista da aldosterona e diurético par tratamento de doenças cardiovasculares
MXPA02001846A (es) Combinacion farmaceutica de antagonistas de la angiotensina ii e inhibidores de la enzima de conversion de la angiotensina i.
FR2848744B1 (fr) Limiteur de puissance de signal hyperfrequence